Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serum Galectin-3: A Potential Marker of Human Papillomavirus Infection Before and After Treatment of Cutaneous Warts

NCT06005389 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT06005389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06005389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serum Galectin-3: A Potential Marker of Human Papillomavirus Infection Before and After Treatment of Cutaneous Warts
Lead sponsor
Assiut University
Phase
Observational
Overall status
Completed
Start date
December 1, 2021
Completion date
February 1, 2023
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection